AACC 2022 -- Vitamin B12 is necessary for many processes in the body and is a cofactor in methylmalonic acid (MMA) metabolism. Vitamin B12 deficiency may present with few symptoms, however chronic deficiency may lead to macrocytic anemia, peripheral nerve damage and memory impairment.

Welcome to the July 2022 Labcorp Drug Development Decentralized Clinical Trial (DCT) blog. This month, we are going to review our recent presence at several important industry events and provide you with links to a new case study and a just-released video about our snapClinical® technology platform.

An idiotype is a unique antigen-binding site in an antibody and is made up of several epitopes in the variable region. Antibodies raised against the idiotype of a given antibody are called anti-idiotypic antibodies or commonly anti-Ids.

We recently spoke with Daniel Sikkema, executive director of global immunochemistry at Labcorp, regarding bioanalytical support for cell and gene therapy modalities.

Oncology trials are often multisite, multicountry large- scale endeavors, requiring collection of a wide range of data from participants. Traditionally, oncology trials have only been carried out at specialist hospitals with the infrastructure to support patients receiving experimental treatments.

ICEM 2022 -- Early screening for in vitro genotoxicity can remove potential hazards and identify lead candidates for further development.

The global pandemic, supply chain disruptions and unprecedented world events have created unique challenges for businesses worldwide. Read more about the ways we've addressed these disruptions.

Labcorp Drug Development Mobile Clinical Services (MCS) team has now completed the first global visit utilizing the eSource module of the proprietary Labcorp DCT platform, snapClinical. This module represents a cross-functional effort to develop a solution digitizing the at-home trial service workflow.

A leading cause of blindness, GA affects more than 5 million people worldwide and 1 million in the United States alone. This investigational targeted C3 therapy helps regulate excessive activation of the complement cascade within the immune system, a known contributor to the progression of many serious diseases.

Labcorp was approached by the manufacturer of three closely related flavorings due for renewal of authorization. Part of the reauthorization required a new updated suite of studies.